Word from Immix Biopharma Inc. of updated data due with NXC-201 brought to the forefront an ongoing push by drug developers to come up with a treatment for AL amyloidosis. Immix has the only CAR T therapy in the works for the disease, and the principal investigator in the Nexicart-1 phase Ib/IIa effort is slated to speak May 19 during the annual meeting of the American Society of Gene & Cell Therapy.
New and updated preclinical data presented at the American Society of Gene & Cell Therapy Congress in Los Angeles, by: 2seventy Bio, Dyne Therapeutics, In8bio, Kelonia Therapeutics, Siren Biotechnology, Umoja Biopharma.
Currently, there is no FDA-approved drug for nonalcoholic steatohepatitis (NASH), which has evolved into the second leading cause of liver transplantation in the U.S. Researchers from Children’s Hospital Los Angeles and Epigen Biosciences Inc. disclosed preclinical data on EPGN-2154, a novel lysophosphatidic acid LPA1 receptor agonist that has already demonstrated antifibrotic activity in preclinical kidney and liver models.
Dihydroorotate dehydrogenase (DHODH) is an enzyme ubiquitously expressed in all tissues whose inhibition has proven effective in preventing viral replication. Previous knowledge on DHODH inhibitor vidofludimus calcium demonstrated that this compound inhibits viral replication of DNA, RNA and retroviruses and induces innate immune responses that lead to an antiviral state thus inhibiting virus reactivation.
The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose of the gene therapy against type 2 diabetes (T2D) and obesity that Fractyl Health Inc. is developing. Scientists from the Lexington, Mass.-based company have designed a strategy based on glucagon-like peptide-1 (GLP-1) to transform pancreatic cells and reverse the disease.
Researchers from Kyushu University and Mochida Pharmaceuticals Co. Ltd. disclosed recent data along with the chemical structure of PAM-369, a novel muscarinic acetylcholine M3 receptor positive allosteric modulator (PAM), being developed for the potential prevention or treatment of NSAID-induced enteropathy.
Researchers from Aligos Therapeutics Inc. and the Katholieke Universiteit Leuven reported on the preclinical activity of ALG-097558, a novel oral available 3CL protease inhibitor with pan-coronavirus antiviral activity.
PARP14 is an ADP-ribosyltransferase that transfers ADP-ribose from NAD+ onto the appropriate protein target. PARP14 selectively binds to STAT6 and promotes expression of IL-4-regulated genes, thus modulating inflammatory signaling pathways. PARP14 is overexpressed in tissues from patients with dermatomyositis, atopic dermatitis, psoriasis and other inflammatory disorder cells compared to normal tissues.
New and updated preclinical data presented at the American Society of Gene & Cell Therapy Congress in Los Angeles, by: Abeona Therapeutics, Arsenal Biosciences, Cimeio Therapeutics, Homology Medicines, Locanabio, Precision Biosciences, Wave Life Sciences.